Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million
Rhea-AI Summary
Jupiter Neurosciences (NASDAQ: JUNS) signed a definitive license agreement with PharmAla Biotech Holdings for perpetual, exclusive U.S. rights to ALA-002, a patented, FDA-designated Novel Chemical Entity based on non-racemic MDMA. The transaction is valued at up to $100 million, excluding ongoing royalties, and converts Jupiter from a single-program to a dual clinical-stage CNS company alongside its Phase II Parkinson’s program JOTROL.
According to Jupiter, deal terms include a $3.3 million upfront payment ($1.5 million cash and $1.8 million in JUNS stock with a 120-day lock-up), a $3.3 million Phase 3 first-patient-in milestone, a $20 million U.S. NDA approval milestone, and commercial milestones of $10 million, $30 million, and $33.3 million at cumulative U.S. net sales of $333 million, $1 billion, and $2 billion, respectively. A 3% royalty on net sales begins after the third commercialization milestone. PharmAla will continue to manufacture ALA-002 for Jupiter under negotiated commercial terms, and management highlights alignment with a 2026 U.S. Executive Order aimed at accelerating psychedelic therapies.
Positive
- Deal value up to $100M in milestones plus 3% royalties after thresholds
- $3.3M upfront consideration split between $1.5M cash and $1.8M JUNS stock
- Diversification to dual clinical-stage CNS pipeline with JOTROL and ALA-002
- Perpetual, exclusive U.S. rights to FDA NCE-designated ALA-002
- Regulatory advantages via NCE status with five-year data exclusivity upon approval
- GMP supply secured as PharmAla continues manufacturing ALA-002 for Jupiter
Negative
- Milestone obligations up to ~$96.6M beyond upfront payment, if all milestones are achieved
- 3% royalty on net sales payable after the third commercialization milestone
- $1.8M equity component in upfront payment may dilute existing shareholders
News Explained
The agreement adds a $1.5 million cash obligation against $2,362,749 of reported March 31, 2026 cash; stock dilution remains unquantified.
The definitive license agreement includes a
The release gives no share count or issuance price for the
At
Sources and calculations
- Jupiter Neurosciences announcement of definitive ALA-002 license agreement (2026-07-21)
- Jupiter Neurosciences first-quarter 2026 fundamentals (2026Q1)
- Cash and equivalents vs quarterly operating cash outflow, in days of cash use $2,362,749 / ($1,432,100 / 90) = [object Object]
Market reaction: JUNS +27.15% on ALA-002 partnership
Following this news, JUNS has gained 27.15%, reflecting a significant positive market reaction. Our momentum scanner has triggered 18 alerts so far, indicating notable trading interest and price volatility. The stock is currently trading at $0.21. This price movement has added approximately $2M to the company's valuation. Trading volume is exceptionally heavy at 13.0x the average, suggesting very strong buying interest.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 07 | Board appointment | Neutral | -2.4% | Philipson joined the Board and was assigned to Audit and Compensation Committees. |
| May 27 | Phase 2 enrollment | Positive | +4.3% | Enrollment began for the 30-patient, 12-week randomized RESET Parkinson’s study. |
| May 21 | Registered direct offering | Negative | -12.2% | Company closed a $2.0 million offering intended to support trials and debt reduction. |
| May 20 | Registered direct offering | Negative | +10.3% | Company priced 7,142,858 shares in an offering expected to raise $2.0 million. |
| May 20 | ALA-002 term sheet | Positive | +10.3% | Company signed a term sheet for perpetual exclusive U.S. rights to ALA-002. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
JUNS's recent news reactions were mixed: three of five events aligned with the announcement's positive framing, while two diverged.
Key Terms
novel chemical entity regulatory
non-racemic medical
data exclusivity regulatory
gmp technical
breakthrough therapy designation regulatory
nda regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Transaction expands Jupiter into a dual clinical-stage CNS company by adding a differentiated FDA-designated Novel Chemical Entity alongside its Phase II Parkinson’s disease program
JUPITER, FL, July 21, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) today announced that it has entered into a definitive license agreement with PharmAla Biotech Holdings Inc. for perpetual exclusive U.S. rights to ALA-002. The transaction has a potential value of up to
Transaction Highlights
- Deal Value: Up to
$100M (including milestone payments; exclusive of ongoing royalties) - Upfront Payment:
$3.3M ($1.5M cash +$1.8M JUNS common stock, 120-day lock-up) - Development Milestone:
$3.3M upon Phase 3 First Patient In - Regulatory Milestone:
$20M upon U.S. NDA Approval - Commercial Milestones:
$10M /$30M /$33.3M at$333M /$1B /$2B cumulative U.S. net sales - Royalty:
3% of net sales (commencing after third commercialization milestone) - Asset: ALA-002 — FDA NCE-designated, non-racemic MDMA (patented)
- Rights Granted: Perpetual, exclusive to United States
About ALA-002
ALA-002 is a patented, non-racemic MDMA formulation that has received Novel Chemical Entity (NCE) designation from the U.S. Food and Drug Administration (FDA), providing enhanced regulatory protection and a five-year data exclusivity period upon approval. ALA-002 has been engineered to deliver materially improved cardiovascular safety and reduced abuse liability compared to racemic MDMA while preserving the pro-social and therapeutic properties central to MDMA-assisted psychotherapy. PharmAla’s MDMA supply is currently active in U.S. government-sponsored VA and DHA clinical trials. ALA-002 targets a U.S. psychedelic therapeutics market estimated at
GMP Drug Supply
PharmAla is a globally recognized manufacturer and supplier of MDMA for clinical use, with supply contracts for clinical trials on 3 continents, and serving such institutions as the US Veterans Affairs Administration and several Ivy League universities. Under the terms of the Definitive Agreement, PharmAla will continue to manufacture ALA-002 drug product for Jupiter under commercial terms to be negotiated, greatly accelerating Jupiter’s development timelines.
Executive Order and Regulatory Alignment
On April 18, 2026, President Donald J. Trump signed a landmark Executive Order titled “Accelerating Medical Treatments for Serious Mental Illness,” directing the FDA and DEA to expand access to investigational psychedelic therapies. Key provisions include: a Right to Try pathway for eligible patients; Commissioner’s National Priority Vouchers enabling 1–2 month expedited FDA review timelines for psychedelic drugs with Breakthrough Therapy designation; and
Management Commentary
“This agreement significantly expands our CNS strategy by adding a differentiated clinical-stage asset that complements our Parkinson's disease program. We believe ALA-002 addresses a large unmet medical need and provides Jupiter with a second independent development opportunity. Our focus is now disciplined clinical execution, prudent capital allocation and advancing both programs toward meaningful value-creating milestones, while recognizing the inherent risks of clinical development.” — Christer Rosén, Chairman and Chief Executive Officer, Jupiter Neurosciences
— Christer Rosén, Chairman and Chief Executive Officer, Jupiter Neurosciences
“This agreement broadens our strategic reach in CNS and brain plasticity while strengthening our shareholders’ equity and establishing a clear path to build long-term value through disciplined clinical and regulatory execution in the United States. We’ve spent the past few months aligning strategy and mobilizing for execution in the space of psychedelic medicines, exemplified by the two new experts we have brought onto our Board of Directors. Drs. Tomas Philipson and Andrew Cutler. The next 12 months will be transformative for Jupiter.: .”
— Alison Silva, President and Chief Business Officer, Jupiter Neurosciences
“PharmAla developed ALA-002 with the goal of delivering a greatly improved MDMA-based therapeutic candidate, with an improved safety profile, for patients who need better treatment options for a range of neuropsychiatric disorders. While PharmAla will continue to advance ALA-002 outside of the United States, Jupiter’s focus on CNS disorders and its commitment to advancing innovative brain therapies in the United States make this a strong strategic fit for both companies.”
— Nicholas Kadysh, Founding Chief Executive Officer, PharmAla Biotech Holdings Inc.
About Jupiter Neurosciences, Inc.
Jupiter Neurosciences, Inc. (NASDAQ: JUNS) is a clinical-stage biopharmaceutical company advancing a therapeutic pipeline targeting central nervous system disorders and neuroinflammation. The Company’s present lead program, JOTROL™ — a proprietary, enhanced-bioavailability resveratrol formulation — is currently in a Phase IIa clinical trial for Parkinson’s disease. JUNS also commercializes Nugevia™, a consumer longevity supplement. The acquisition of exclusive U.S. rights to ALA-002 further strengthens the Company’s CNS pipeline by adding a next-generation, patented psychedelic NCE at a pivotal moment in U.S. regulatory policy. For more information, visit www.jupiterneurosciences.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, statements regarding the expected benefits of the Agreement, the closing of the transaction, the issuance of shares of JUNS common stock, the potential development, regulatory approval, commercialization, market opportunity, safety profile, abuse-liability profile, data exclusivity, and therapeutic potential of ALA-002, the potential achievement and timing of milestone payments and royalties, Jupiter’s ability to fund and execute development and commercialization activities, the availability or applicability of regulatory pathways or federal initiatives for investigational psychedelic therapies, and the potential impact of the April 18, 2026 Executive Order on Jupiter, ALA-002, or the psychedelic medicine sector. These statements are based on current expectations and assumptions and are subject to substantial risks and uncertainties, including risks relating to the satisfaction of closing conditions, Jupiter’s reliance on PharmAla and other third parties, the early-stage and investigational nature of ALA-002, unexpected safety or efficacy data, clinical trial timing, site activation and enrollment, regulatory review and approval, DEA scheduling, intellectual property protection, market acceptance, competition, Jupiter’s capital requirements and ability to obtain additional financing, and the other risks described under “Risk Factors” in Jupiter’s filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date of this press release, and Jupiter undertakes no obligation to update or revise them except as required by law.
Investor Relations Contact
Jupiter Neurosciences, Inc.
ir@jupiterneurosciences.com
Tel: +1 561 406 6154
c.rosen@jupiterneurosciences.com
a.silva@jupiterneurosciences.com
SOURCE: Jupiter Neurosciences, Inc.
© 2026 Jupiter Neurosciences, Inc. All rights reserved. JOTROL™ and Nugevia™ are trademarks of Jupiter Neurosciences, Inc. LaNeo™ is a trademark of PharmAla Biotech Holdings Inc.
